Test Price
2,800 AEDโ Home Collection Available
๐ Results in 3โ4 Weeks (expedited available)
MLH1 Gene Mismatch Repair Cancer Syndrome Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS & Sanger Confirmation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counsellors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- UAE Regulatory Compliance: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability.
Test Overview & Methodology
This NGS test screens the entire MLH1 gene for germline mutations linked to Lynch syndrome, a hereditary cancer predisposition syndrome. By identifying pathogenic variants early, patients can access life-saving surveillance and preventive strategies.
| Feature | Our Test (Precision Genetic Hub) | Closest Alternative (Legacy Sanger) |
|---|---|---|
| Methodology | NGS with full gene coverage + MLPA for large rearrangements | Sanger sequencing of select exons only |
| Turnaround Time | 3โ4 Weeks (expedited available) | 6โ8 Weeks |
| Sensitivity / Detection Rate | >99.9% for SNVs, indels, CNVs (ISO-validated) | ~85% (misses deep intronic and large rearrangements) |
| Clinical Interpretation | DHA-licensed report with ACMG 2020 classification & hereditary cancer risk analysis | Generic lab report without personalised risk counselling |
Physician Insight & Safety Protocols
"A positive MLH1 finding indicates a hereditary predisposition to Lynch syndrome, not an active cancer diagnosis. Proactive surveillance and a multidisciplinary care approach are essential for managing this inherited risk effectively."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medical Advisory โ Medication Stability
This genetic test evaluates inherited cancer susceptibility. Do not alter any prescribed medications without consulting your physician.
Exclusion Criteria & Emergency Red Flags
- Not suitable for acute leukemia diagnosis or somatic tumour profiling.
- Do not use as a standalone pharmacogenomic test for chemotherapy selection.
- If you experience sudden abdominal pain, rectal bleeding, or jaundice, seek emergency care immediately โ these symptoms require urgent evaluation unrelated to this test.
- Positive result warrants urgent referral to oncology and gastroenterology for colonoscopic surveillance from age 20โ25.
Patient FAQ & Clinical Guidance
1. What is the MLH1 gene test and what does it detect?
This test identifies inherited pathogenic variants in the MLH1 gene associated with Lynch syndrome. A positive result indicates a significantly elevated lifetime risk for colorectal, endometrial, and other cancers, enabling tailored surveillance and preventive measures.
2. How is the sample collected for this genetic test?
A DHA-licensed phlebotomist collects a small peripheral whole blood sample (3โ5 mL in EDTA tube) at your home using an ISO-certified cold-chain kit. The procedure is minimally invasive, follows strict infection control protocols, and is available daily from 8 AM to 11 PM.
3. Will my genetic data remain confidential under UAE law?
Yes, your DNA sequence and clinical data are encrypted and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. No third-party sharing occurs without your explicit consent.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic and personal data are processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Your information is encrypted, access-controlled, and never shared with third parties without explicit consent.
Healthcare Technology Compliance: This test fully adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health records and telemedicine protocols.
Medical Liability: Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing your rights throughout the testing process.
Clinical & Logistical Metadata
| Test Name | MLH1 Gene Mismatch Repair Cancer Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks (expedited available) |
| Sample Type / Matrix | Peripheral Whole Blood (3โ5 mL in EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage, MLPA for large rearrangements, and Sanger confirmation |
| ICD-10-CM Code | Z15.09, Z80.0 |
| LOINC Code | 21629-9 |
| DHA Facility License & Laboratory Address | License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
[]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians